Medaglip SR 100
Medaglip SR 100 - Image 2
Medaglip SR 100 - Image 3
,

Medaglip SR 100

Composition:

  • Vildagliptin IP 100 mg (Sustained Release)
    Therapeutic Class:

  • DPP-4 Inhibitor (Dipeptidyl Peptidase-4 Inhibitor)
    Schedule: Schedule H (Prescription Drug)

Medaglip SR 100 contains Vildagliptin, a DPP-4 inhibitor that enhances incretin hormone activity to regulate blood glucose in patients with Type 2 Diabetes Mellitus (T2DM). This once-daily sustained-release formulation provides steady glycemic control with improved patient compliance.

It is especially beneficial in patients with mild to moderate hyperglycemia, elderly individuals, and those at risk of hypoglycemia.

Usage of Medaglip SR 100

Medaglip SR 100 is indicated for:

  • Type 2 Diabetes Mellitus (as monotherapy or in combination)

  • Patients inadequately controlled by metformin, sulfonylureas, or insulin

  • Diabetics who are elderly, obese, or have renal limitations

  • Preferable for those needing low hypoglycemia risk and weight neutrality

Mechanism of Action

  • Inhibits DPP-4 enzyme, which degrades GLP-1 and GIP (incretins)

  • Increased incretin levels →
    🔹 Enhanced insulin secretion in response to meals
    🔹 Suppressed glucagon secretion
    🔹 Reduced hepatic glucose output

  • Results in postprandial and fasting glucose reduction

Key Benefits

✅ Effective HbA1c reduction (~0.7–1.0%)
✅ Weight-neutral
✅ Minimal risk of hypoglycemia
✅ Convenient once-daily sustained release dosing
✅ Safe in elderly and renal-compromised patients (with dose adjustments)

Common Side Effects

  • Headache

  • Dizziness

  • Nausea or constipation

  • Mild peripheral edema (rare)

  • Transient increase in liver enzymes (monitoring recommended)

Precautions

  • Not recommended in Type 1 diabetes or diabetic ketoacidosis (DKA)

  • Use with caution in patients with hepatic impairment

  • Monitor liver function tests (LFTs) periodically

  • Adjust dose in renal impairment (especially if eGFR < 60 ml/min)

Drug Interactions

  • Generally well tolerated in combination therapy

  • Can be used with:
    🔹 Metformin
    🔹 Sulfonylureas (monitor for hypoglycemia)
    🔹 Thiazolidinediones
    🔹 Insulin

  • Does not induce or inhibit CYP enzymes significantly

Dosage and Administration

  • One tablet daily, preferably with breakfast

  • May be used as monotherapy or add-on therapy

  • In renal impairment:

    • eGFR 50–80 mL/min: Use 50 mg once daily

    • eGFR < 50 mL/min: Not recommended or use cautiously under monitoring

Storage

  • Store below 25°C, protected from light and moisture

  • Keep out of reach of children

Patient Counseling Points

  • Take at the same time every day

  • Report symptoms such as jaundice, fatigue, or upper abdominal pain (possible liver issues)

  • Inform the doctor about any other medications or supplements

  • Continue regular exercise and dietary control

  • Routine blood sugar and LFT monitoring is essential

Related products

Review My Order

0

Subtotal

Taxes & shipping calculated at checkout

Checkout